BetterLife Pharma Celebrates Legal Victory
Recently, BetterLife Pharma Inc. (“BetterLife”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), a rapidly growing biotech company based in Vancouver, announced a favorable outcome regarding its legal claims in New York. This victory reinforces the company's focus on developing innovative treatments while navigating the rigors of the legal landscape.
The Legal Dispute: An Overview
The legal claim was initiated by a former director of BetterLife’s subsidiary, MedMelior Inc. (previously known as Altum Pharmaceuticals), who sought a substantial $12.5 million in damages. The case was filed back in early 2021 and has undergone several legal proceedings.
Recent Court Decisions
In recent months, BetterLife secured positive judgments in both state and federal courts in New York, successfully leveraging the 'forum non conveniens' doctrine to dismiss the claims. After the last ruling, the former director attempted to appeal but ultimately chose not to proceed. As a result, the legal issue was concluded without any financial penalties or obligations on BetterLife’s part.
The Company’s Response
Dr. Ahmad Doroudian, CEO of BetterLife, expressed his satisfaction with the judgment, stating, “We are very pleased with the resolution of this case. We always believed the case to be without merit and were confident that there will be a successful conclusion for BetterLife and MedMelior.” This statement highlights the company’s confidence in its legal position and commitment to its mission.
About BetterLife Pharma: Focused on Innovation
BetterLife Pharma is primarily centered on developing groundbreaking treatments for neuropsychiatric and neurological conditions. The company is dedicated to enhancing the quality of life for individuals suffering from various disorders.
Key Products in Development
The lead candidate, BETR-001, is a non-hallucinogenic derivative of LSD, currently undergoing preclinical and IND-enabling studies. Notably, BETR-001 stands out as it is self-administered, owing to its unregulated status. The synthesis patent for BETR-001 facilitates a smoother path through regulatory challenges. The pending patent encompasses its application for treating major depressive disorder, anxiety disorders, and neuropathic pain.
Research and Future Prospects
Additionally, BetterLife is advancing BETR-002, which is based on honokiol, an active compound from magnolia bark, specialized in treating anxiety disorders, including those related to benzodiazepine dependency. The pending patents further support its innovative formulations and usage.
Strategic Alternatives for Viral Treatment
Beyond its primary compounds, BetterLife is also exploring strategic opportunities for a drug candidate aimed at treating viral infections. This approach signifies the company's broad vision in addressing various health challenges.
Contact Information
If you require further information or have inquiries, please reach out to:
David Melles, Investor Relations Manager
Email: David.Melles@blifepharma.com
Phone: 1-778-887-1928
Frequently Asked Questions
1. What is the outcome of BetterLife's legal case?
The legal claims against BetterLife have concluded favorably, resulting in no obligations for the company.
2. Who initiated the legal claim against BetterLife?
A former director of BetterLife's subsidiary, MedMelior, filed the claim for damages.
3. What are the primary products developed by BetterLife?
BetterLife is focused on two main compounds: BETR-001 for neuro-psychiatric disorders and BETR-002 for anxiety-related disorders.
4. Where is BetterLife Pharma based?
BetterLife Pharma is located in Vancouver, British Columbia.
5. How can I contact BetterLife for more information?
You can contact David Melles at David.Melles@blifepharma.com or call 1-778-887-1928.
